{
    "clinical_study": {
        "@rank": "30040", 
        "arm_group": {
            "arm_group_label": "Blood Draw", 
            "arm_group_type": "Other", 
            "description": "Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting"
        }, 
        "brief_summary": {
            "textblock": "The current proposal extends work done in mouse models evaluating the consistency of\n      measuring RLIP76 in a clinical cohort (Aim 1) by using guidelines provided by the NIH for\n      validating biomarkers. We will also proceed to estimate the effect size of a potential\n      correlation of RLIP76 with standard MsY treatment measures such as hgbA1c, LDL, and\n      triglyceride levels in a longitudinal prospective study ( Aim 2) that will follow a cohort\n      of patients with MsY who seek care at the City of Hope Endocrine clinic over a 12 month\n      period.."
        }, 
        "brief_title": "Validation of an RLIP76 Assay in Humans", 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Metabolic Syndrome X"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Registered patient of City of Hope and followed in the Endocrine Clinic. Must have\n             documentation of a diagnosis of diabetes identified by the problem list in the\n             patient's electronic health record.\n\n          -  Must demonstrate features of MsY by possessing any of the following characteristics\n             and/or receiving treatment for diabetes, hyperlipidemia, and/or hypertriglyceridemia.\n\n               -  Central obesity: waist circumference \u2265 102 cm or 40 inches (male), \u2265 88 cm or 36\n                  inches (female)\n\n               -  Dyslipidemia: TG \u2265 1.7 mmol/L (150 mg/dl)\n\n               -  Dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female)\n\n               -  Blood pressure \u2265 130/85 mmHg\n\n               -  Fasting plasma glucose \u2265 6.1 mmol/L (110 mg/dl)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01824017", 
            "org_study_id": "12044"
        }, 
        "intervention": {
            "arm_group_label": "Blood Draw", 
            "intervention_name": "Blood Draw", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 2 diabetes", 
            "metabolic syndrome", 
            "oxidative stress", 
            "GSH"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "last_name": "Raynald Samoa, MD", 
                "phone": "800-826-4673"
            }, 
            "contact_backup": {
                "last_name": "Sanjay Awasthi, MD", 
                "phone": "800 826-4673"
            }, 
            "facility": {
                "address": {
                    "city": "Duarte", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91010"
                }, 
                "name": "City of Hope Medical Center"
            }, 
            "investigator": {
                "last_name": "Raynald Samoa, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Validation of RLIP76 Assay and Exploratory Study of RLIP76 Correlation Among Patients With Type 2 Diabetes and Metabolic Syndrome", 
        "overall_contact": {
            "last_name": "Sachiko Paz", 
            "phone": "800 826-4673"
        }, 
        "overall_contact_backup": {
            "last_name": "Raynald Samoa, MD", 
            "phone": "800 826-4673"
        }, 
        "overall_official": {
            "affiliation": "City of Hope Medical Center", 
            "last_name": "Raynald Samoa, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The investigators will perform 6 repeated measurements on first blood draws from patients with Type 2 diabetes who also have MsY. Sixty-seven percent (4 out of 6) of the quality controls must be within 15% of the mean of these measurements for us to consider the ELISA-based RLIP76 assay to be consistent", 
            "measure": "The consistency of an ELISA-based RLIP76 assay in the serum of human subjects with metabolic syndrome.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01824017"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The investigators will perform a longitudinal correlative study to evaluate the correlation of RLIP76 levels with changes in treatment measures of metabolic syndrome, such as hemoglobin A1c, LDL, and triglyceride levels. The results of this objective will be used to design a correlative study to determine the correlation of RLIP76 levels to the change in treatment measures of metabolic syndrome.", 
            "measure": "Effect size of correlation of RLIP76 levels with treatment measures of metabolic syndrome such as hemoglobin A1c, LDL, and triglyceride levels.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "City of Hope Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "City of Hope Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}